Brensocatib

We’re investigating brensocatib, a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), as a potential treatment for neutrophil-mediated diseases, including bronchiectasis and chronic rhinosinusitis without nasal polyps. Brensocatib is an investigational product that has not been approved for any indication in any jurisdiction.

Find available clinical trials